Literature Review : Hubungan antara Kejadian Hiperurisemia pada Pasien Congestive Heart Failure

Nadiyah Nurfadhilah; Akina Maulidhany Tahir; Endy Adnan; Nurhikmawati Nurhikmawati

doi:10.31004/koloni.v5i2.961

Authors

Nadiyah Nurfadhilah Universitas Muslim Indonesia
Akina Maulidhany Tahir Universitas Muslim Indonesia
Endy Adnan Universitas Muslim Indonesia
Nurhikmawati Nurhikmawati Universitas Muslim Indonesia

DOI:

https://doi.org/10.31004/koloni.v5i2.961

Keywords:

Hyperuricemia; Uric acid; Congestive heart failure

Abstract

Congestive heart failure (CHF) is a progressive clinical syndrome associated with high morbidity and mortality. Hyperuricemia has been suggested to contribute to the development and progression of CHF through several pathophysiological mechanisms, including oxidative stress, endothelial dysfunction, inflammation, and ventricular remodeling. This literature review aimed to evaluate the association between hyperuricemia and the incidence, severity, complications, and prognosis of CHF based on current scientific evidence. A narrative literature review was conducted using secondary data obtained from national and international scientific journals, textbooks, and other relevant scientific sources published between 2015 and 2026. The reviewed evidence consistently demonstrated that hyperuricemia is associated with poorer clinical outcomes in patients with heart failure. Elevated serum uric acid (UA) levels were correlated with higher New York Heart Association (NYHA) functional class, impaired hemodynamic status, increased risk of CHF occurrence, hospital readmission, and mortality across various heart failure phenotypes. Several studies also identified serum UA as an independent predictor of disease severity and prognosis in patients with heart failure. In conclusion, hyperuricemia is significantly associated with the severity and clinical outcomes of CHF and may serve as an important prognostic biomarker. However, current evidence regarding the effectiveness of uric acid-lowering therapy in improving heart failure prognosis remains inconsistent; therefore, serum UA cannot yet be recommended as a definitive therapeutic target.

References

Alshamari, A. H. I., Kadhim, R. K., & Al-Mohana, S. J. A. (2022). The effect of serum uric acid concentration on the severity of chronic congestive heart failure. Journal of Medicine and Life.

Arnold, S. V., Silverman, D. N., Gosch, K., Nassif, M. E., Infeld, M., Litwin, S., et al. (2023). Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction. JACC: Heart Failure.

Borghi, C., Agabiti-Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redon, J., Stack, A. G., & Tsioufis, K. P. (2020). Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. European Journal of Internal Medicine, 80, 1–11. https://doi.org/10.1016/j.ejim.2020.07.006

Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J. V., Deschaseaux, C., et al. (2017). Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: A network meta-analysis. Circulation: Heart Failure.

De Groote, P., Ennezat, P. V., & Mouquet, F. (2017). Bisoprolol in the treatment of chronic heart failure. Vascular Health and Risk Management.

Deis, T., Rossing, K., Ersboll, M. K., Wolsk, E., & Gustafsson, F. (2022). Uric acid in advanced heart failure: Relation to central haemodynamics and outcome. Open Heart.

Elmobark, S., Hamad, F., Hassan Mutwali, L. G., Ali Mohamed Zain, N. Q. A., Mohamed, Z., Mohamed Ahmed, T. A., et al. (2025). Beta-blockers in heart failure with reduced ejection fraction: A systematic review of randomized controlled trials. Cureus.

Fujihashi, T., Sakata, Y., Nochioka, K., Miura, M., Abe, R., Kasahara, S., et al. (2021). Prognostic impacts of serum uric acid levels in patients with chronic heart failure: Insights from the CHART-2 study. ESC Heart Failure.

Gan, T. M., Wang, S. R., Mo, G. L., Li, S. H., Lu, Y. Q., & Li, J. Y. (2025). Machine learning prediction and SHAP interpretability analysis of heart failure risk in patients with hyperuricemia. Frontiers in Cardiovascular Medicine.

Geavlete, O., & Chioncel, O. (2024). Prognostic impact of heart failure pharmacotherapies in acute heart failure: Strong association in mildly reduced ejection fraction. European Journal of Preventive Cardiology.

Gemilang, R. (2025). Analisis efektivitas biaya terapi kombinasi obat golongan ACE inhibitor-beta (Report).

Han, Y., Cao, Y., Han, X., Di, H., Yin, Y., Wu, J., et al. (2023). Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: Insights from the National Health and Nutrition Examination Survey. Journal of Translational Medicine.

Hassan, W., Nila, S. A., Ahmed, M., Okello, D. O., Maqbool, M., Dabas, M. M., et al. (2024). Comparative efficacy and long-term outcomes of beta-blockers alone or in combination with angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: A systematic review. Cureus.

Huang, W. M., Hsu, P. F., Cheng, H. M., Lu, D. Y., Cheng, Y. L., Guo, C. Y., et al. (2016). Determinants and prognostic impact of hyperuricemia in hospitalization for acute heart failure. Circulation Journal.

Kim, S., Lee, K. Y., Kim, K. A., Byeon, J., Shin, S., Hwang, B. H., et al. (2025). The role of serum uric acid in survival prediction in patients with acute myocardial infarction accompanied by heart failure with preserved ejection fraction. Frontiers in Cardiovascular Medicine.

Kwon, Y. E., Ahn, S. Y., Ko, G. J., Kwon, Y. J., & Kim, J. E. (2025). Impact of uric acid levels on mortality and cardiovascular outcomes in relation to kidney function. Journal of Clinical Medicine.

Liu, C. F., Song, K. Y., Zhou, W. N., & Wei, Y. J. (2021). Association between uric acid and in-hospital heart failure in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Disease Markers.

Liu, X., Huang, G., You, Y., Zhang, Y., Wang, T., Zhu, Y., et al. (2024). Hyperuricemia is associated with heart failure readmission in patients with heart failure and preserved ejection fraction: An observational study in Chinese. Nutrition, Metabolism and Cardiovascular Diseases.

Madureira, S., Gouveia, R., Elias, C., Neves, A., Ribeirinho-Soares, P., Amorim, M., et al. (2024). Hyperuricemia is associated with higher mortality in non-diabetic heart failure patients. Cureus.

Matsumoto, S., Henderson, A. D., Shen, L., Kondo, T., Yang, M., Campbell, R. T., et al. (2025). Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure.

Miao, L., Guo, M., Pan, D., Chen, P., Chen, Z., Gao, J., et al. (2021). Serum uric acid and risk of chronic heart failure: A systematic review and meta-analysis. Frontiers in Medicine.

Piepoli, M. F., Salvioni, E., Corrà, U., Doni, F., Bonomi, A., La Gioia, R., et al. (2020). Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction: An analysis from the MECKI score research group. European Journal of Internal Medicine.

Qin, S., Xiang, M., Gao, L., Cheng, X., & Zhang, D. (2024). Uric acid is a biomarker for heart failure, but not therapeutic target: Result from a comprehensive meta-analysis. ESC Heart Failure.

Rufe, N. B., Lamesa, T. A., Mamo, A. G., Zewude, B. M., Addisu, B., Nigusie, D. J., et al. (2025). Hyperuricemia and associated factors among adult cardiovascular disease patients at Salale University Comprehensive Specialized Hospital, Fitche, Central Ethiopia. PLoS ONE.

Shams, P., Malik, A., & Chhabra, L. (2026). Heart failure (Congestive heart failure). In StatPearls. StatPearls Publishing.

Si, K., Wei, C., Xu, L., Zhou, Y., Lv, W., Dong, B., et al. (2021). Hyperuricemia and the risk of heart failure: Pathophysiology and therapeutic implications. Frontiers in Endocrinology.

Si, K., Wei, C., Xu, L., Zhou, Y., Lv, W., Dong, B., Wang, Z., Huang, Y., Wang, Y., & Chen, Y. (2021). Hyperuricemia and the risk of heart failure: Pathophysiology and therapeutic implications. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2021.770815

Sn, V. P., Jaramillo, A. P., Yasir, M., Hussein, S., Singareddy, S., Iyer, N., et al. (2023). Hyperuricemia and its association with the severity and complications of congestive heart failure: A systematic review. Cureus.

Sn, V. P., Jaramillo, A. P., Yasir, M., Hussein, S., Singareddy, S., Iyer, N., & Nath, T. S. (2023). Hyperuricemia and its association with the severity and complications of congestive heart failure: A systematic review. Cureus, 15(9), e45246. https://doi.org/10.7759/cureus.45246

Tang, J., Wang, P., Liu, C., Peng, J., Liu, Y., & Ma, Q. (2025). Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis. Chinese Medical Journal (English).

Tang, J., Wang, P., Liu, C., Peng, J., Liu,Y., & Ma, Q. (2025). Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis. Chinese Medical Journal (English).

Zheng, Y., Chen, Z., Yang, J., Zheng, J., Shui, X., Yan, Y., et al. (2024). The role of hyperuricemia in cardiac diseases: Evidence, controversies, and therapeutic strategies. Biomolecules.

Zulia Tri Rahayu, Retnowati, E., & Kurniawan, G. (2025). Hubungan profil pasien gagal jantung terhadap efektivitas terapi kombinasi antihipertensi di rawat inap RSUD dr. Loekmono Hadi Kudus. Jurnal Ilmiah Kedokteran dan Kesehatan.